Jim Cramer on Nvidia, Intel, Speculative Stocks, and Biotech Picks

Market Dichotomy: Fed vs. Free Will Capitalism

• 💡 The market shows a dichotomy between economists influenced by presidential desires and the free-willing capitalism of the semiconductor business, exacerbated by federal intrusions.
• 📈 The Dow, S&P, and NASDAQ advanced due to a large percentage of money in index funds, which correlate with the bond market; when rates fall, indices rise.
• 🚀 Individual stocks, like Nvidia, are often independent of Federal Reserve actions, demonstrating that not all investments are hostage to interest rates.

Nvidia's Strategic Investment in Intel

• 💰 Nvidia made a $5 billion investment in Intel, seeing its own market cap rally by $150 billion, a "miracle" highlighting the power of strategic investment.
• 📉 Intel, once a semiconductor kingpin, lost market share to AMD under Lisa Su and struggled with its foundry buildout, necessitating government and private investment.
• 🤝 Nvidia's investment provides Intel with a crucial partner for its PC and server business, a sector Nvidia wasn't heavily involved in, creating a win-win scenario.

The Nature of Speculative Investing

• 🤔 Speculation is encouraged, especially for younger investors, but must be done wisely, with a strategy to "scale out" gradually after significant gains.
• 📊 Examples of speculative stocks include richly valued companies with earnings like Palantir (277x earnings), thesis stocks like Bloom Energy and Aqua, and literal rocket ship companies like Rocket Lab.
• ⚠️ While speculation can be rewarding, it carries significant risk, and investors must understand they can lose a great deal of money if wrong.

Biotech Spotlight: Aquestive Therapeutics

• 🔬 Aquestive Therapeutics is developing Anifilm, a dissolvable oral film to replace the EpiPen, offering faster absorption and greater convenience.
• 📈 The stock has seen significant gains due to positive late-stage trial data and FDA submission, but faces a binary outcome: approval or rejection.
• ⚠️ Investors should only consider Aquestive as a speculative pick, understanding that the stock's fate is heavily dependent on the FDA's decision.

Lens Therapeutics: A New Vision for Presbyopia

• 👁️ Lens Therapeutics has developed Viz, an eye drop to treat presbyopia (age-related farsightedness), approved by the FDA.
• 💰 The product is a cash-pay item, priced at $79/month or $198 for three months, with a total addressable market of $3 billion in the US.
• 🚀 While the stock has already seen a significant run-up, the company's success hinges on Viz's efficacy and convenience convincing patients to choose it over reading glasses.